Principal Financial Group Inc. Boosts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

Principal Financial Group Inc. raised its stake in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 1.3% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 841,011 shares of the biopharmaceutical company's stock after purchasing an additional 10,827 shares during the period. Principal Financial Group Inc. owned approximately 0.53% of TG Therapeutics worth $33,161,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in TGTX. Vermillion Wealth Management Inc. bought a new position in TG Therapeutics in the 4th quarter worth approximately $30,000. NBC Securities Inc. boosted its stake in shares of TG Therapeutics by 82,300.0% during the 1st quarter. NBC Securities Inc. now owns 824 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 823 shares during the last quarter. Golden State Wealth Management LLC boosted its stake in shares of TG Therapeutics by 100.0% during the 1st quarter. Golden State Wealth Management LLC now owns 866 shares of the biopharmaceutical company's stock worth $34,000 after buying an additional 433 shares during the last quarter. Quadrant Capital Group LLC lifted its stake in TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock valued at $51,000 after purchasing an additional 975 shares during the last quarter. Finally, USA Financial Formulas bought a new position in TG Therapeutics in the 1st quarter valued at about $57,000. 58.58% of the stock is owned by institutional investors and hedge funds.

TG Therapeutics Stock Performance

Shares of TGTX traded down $0.37 during mid-day trading on Tuesday, hitting $35.61. 2,304,640 shares of the company's stock were exchanged, compared to its average volume of 2,906,322. TG Therapeutics, Inc. has a 52 week low of $16.65 and a 52 week high of $46.48. The company has a quick ratio of 3.04, a current ratio of 4.02 and a debt-to-equity ratio of 1.03. The stock's 50-day simple moving average is $36.65 and its 200-day simple moving average is $35.19. The firm has a market cap of $5.65 billion, a price-to-earnings ratio of 148.38 and a beta of 1.91.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a return on equity of 18.88% and a net margin of 10.13%. The firm had revenue of $120.86 million for the quarter, compared to the consensus estimate of $117.07 million. During the same quarter in the previous year, the business posted ($0.07) EPS. The firm's revenue for the quarter was up 90.4% compared to the same quarter last year. On average, equities research analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current year.

Insider Activity at TG Therapeutics

In other news, Director Yann Echelard sold 10,000 shares of the business's stock in a transaction dated Friday, June 13th. The shares were sold at an average price of $36.94, for a total transaction of $369,400.00. Following the completion of the sale, the director directly owned 228,816 shares of the company's stock, valued at $8,452,463.04. The trade was a 4.19% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 10.64% of the stock is currently owned by insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.